NIKKEI 225
38,419.01 -416.09 (-1.07%) HANG SENG
18,571.22 +91.85 (+0.50%) CRUDE OIL
78.06 -0.32 (-0.41%) GOLD FUTURES
2,315.50 -8.70 (-0.37%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,193.82 -895.97 (-1.75%)
Beam Therapeutics Inc. (BEAM)
After hours:
| Previous close | 22.78 |
| Open | 22.76 |
| Bid | 22.51 x 300 |
| Ask | 22.58 x 200 |
| Day's range | 21.67 - 22.93 |
| 52-week range | 16.95 - 49.50 |
| Volume | |
| Avg. volume | 1,537,826 |
| Market cap | 1.854B |
| Beta (5Y monthly) | 1.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 50.00 |
- GuruFocus.com
Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview
Financial Performance and Strategic Developments Amidst Market Challenges
GlobeNewswireBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities;
ZacksUltragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.02% and 4.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
